









Markets
/
Stocks
/
nasdaq-nby
/

NovaBay Pharmaceuticals Inc

NBY



View Detailed Chart

5.250USD

+2.300+77.97%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

31.56MMarket Cap

0.85P/E TTM



NovaBay Pharmaceuticals Inc

5.250

+2.300+77.97%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+77.97%

5 Days

+87.50%

1 Month

+430.30%

6 Months

+1293.39%

Year to Date

+1221.52%

1 Year

+1398.83%

View Detailed Chart

TradingKey Stock Score of NovaBay Pharmaceuticals Inc

Currency: USD Updated: 2025-12-19

Key Insights

NovaBay Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 133/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 0.85.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NovaBay Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

133 / 158

Overall Ranking

488 / 4582

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.850

Target Price

-18.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

NovaBay Pharmaceuticals Inc Highlights

StrengthsRisks

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.78M.

Overvalued

The company’s latest PE is 0.85, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.37M shares, decreasing 5.68% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 84.49K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.07.